The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Open accessAbstract
Alzheimer’s disease is the world’s most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer’s disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer’s disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3−/− or Casp1−/− mice carrying mutations associated with familial Alzheimer’s disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer’s disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer’s disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer’s disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rat research has identified the NLRP3-ASC inflammasome as a major mechanism through which microglia may drive pathological features of AD [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both beta-amyloids and tau can activate the NLRP3-ASC inflammasome within microglia [92,93].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3 (NLRP3), within microglia recruits the adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) to form an inflammasome complex.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ITGAM/CD11b (or CR3A), is a cell surface receptor involved in activation, migration and phagocytosis of immune cells, so much so that ITGAM/CD11b is used as a marker of activated microglia (Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis et al., 2016).”
From Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk (2019) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In APP/PS1 mice model, NLRP3 knockout reduced Aβ deposition by enhancing phagocytic clearance capacity and increasing extracellular Aβ degradation by insulin- degrading enzyme (IDE).354”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [354]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NLRP3 or caspase-1 knockdown in AD mouse models has yielded promising results in decreasing Aβ accumulation, improving spatial memory, and alleviating other AD-related symptoms (Heneka et al., 2013).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablation of Nlrp3 or Casp1 in APP/PS1 mice rescued spatial memory and behavioral deficits, LTP suppression and spine loss observed in these mice [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, another study reported strongly increased levels of active caspase-1 in early-onset AD and LOAD patients as well as in MCI individuals [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This inflammasome complex is responsible for the production of IL-1 beta, which is a proinflammatory cytokine.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“IL-1 beta was shown to exacerbate tau pathologies [97] and reduce microglial phagocytic activity [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, microglial function may also be of relevance to cognitive performance, as suggested by recent experimental data, which showed that improved microglial clearance was protective in terms of memory function (17).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Proinflammatory environments and signalling are a prominent observation in AD brain pathology [39].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The decreased plaque deposition was also related to increased levels of the proteolytic enzyme insulin-degrading enzyme (IDE) [77], previously reported to degrade Aβ [83].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD [18].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [18]
In the citing paper
“One of the key biological functions of CASP1 is the cleavage of prointerleukin-1β (IL-1β) into the mature biological active cytokine, which is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Preclinical studies support the concept that CASP1-directed increase of IL-1β can augment the deposition of β-amyloid within the brain to worsen Alzheimer's symptoms.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“CASP1, an essential component of NLPR3 inflammasomes, encodes a cysteine protease that is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Notably, Aβ also can activate NF-κB signaling and the NLRP3-ASC inflammasome [426, 427], suggesting that Aβ and tau share common mechanisms in microglia activation.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [427]
In the citing paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [131]
In the citing paper
“Microglia express multiple receptors that can bind Aβ and trigger inflammation, such as CD36 (105), TLR2, TLR4, TLR6 (17), and NLRP3 (106)”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [106]
In the citing paper
“NLRP3 and caspase-1 genetic deletion results in decreased Aβ deposition, reduced IL-1β release from microglia and improved cognitive performance in APPPS1 mice (Heneka et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Toll-like receptors and NOD-like receptors have been previously implicated in the microglia response to Aβ accumulation and shown to mediate an inflammatory response that contributes to pathology”
From TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) · cites this paper as Heneka et al., 2013
In the citing paper
“Animal studies confirmed this significant involvement of NLRP activation, as APP/PS1 mice, lacking the expression of ASC, caspase-1, or NLRP3 had significantly reduced hippocampal and cortical amyloid plaque deposition and ameliorated disease outcome (229, 230).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [230]
In the citing paper
“Recently, an alternative pathway has been described for intracellular signaling produced by the binding of Aβ to microglial cells, activating NLRP3 inflammasome (Heneka et al., 2013; Sheedy et al., 2013).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C. G., McDowell, J., Paskind, M. P., Rodman, L., Salfeld, J. G., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,408
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Cytokines, including IL-1 β , were found to impair microglial clearance functions 16,17 .”
Bevins, R. A., & Besheer, J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.205 · Cited by 1,278
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Cited by
Sorted by citations
Items 301–400 of 1,031
CXCL1 and CXCL2 Regulate NLRP3 Inflammasome Activation via G-Protein–Coupled Receptor CXCR2
Boro, M., & Balaji, K. N. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700129 · Cited by 167
Neuroimmune Connections in Aging and Neurodegenerative Diseases
Scheiblich, H., Trombly, M., Ramirez, A., & Heneka, M. T. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.002 · Cited by 166
Self-citationInnate immune activation in neurodegenerative diseases
Castro‐Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 176
Self-citationInflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts
Mamik, M. K., & Power, C. (2017) · Brain · doi:10.1093/brain/awx133 · Cited by 169
Li, M., Zheng, H.-L., Luo, Y., He, J.-G., Wang, W., Han, J., Zhang, L., Wang, X., Ni, L., Zhou, H.-Y., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.76 · Cited by 163
Mitochondrial Oxidative Stress and “Mito-Inflammation”: Actors in the Diseases
Patergnani, S., Bouhamida, E., Leo, S., Pinton, P., & Rimessi, A. (2021) · Biomedicines · doi:10.3390/biomedicines9020216 · Cited by 178
The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimer’s disease
Milner, M. T., Maddugoda, M. P., Götz, J., Burgener, S. S., & Schroder, K. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.10.011 · Cited by 162
Luo, H., Mu, W.-C., Karki, R., Chiang, H.-H., Mohrin, M., Shin, J. J., Ohkubo, R., Ito, K., Kanneganti, T.-D., & Chen, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.101 · Cited by 161
The “ins and outs” of complement‐driven immune responses
Freeley, S. J., Kemper, C., & Friec, G. L. (2016) · Immunological Reviews · doi:10.1111/imr.12472 · Cited by 166
Mouton‐Liger, F., Rosazza, T., Sepulveda‐Diaz, J., Ieang, A., Hassoun, S., Claire, E., Mangone, G., Brice, A., Michel, P. P., Corvol, J., et al. (2018) · Glia · doi:10.1002/glia.23337 · Cited by 160
The basis of cellular and regional vulnerability in Alzheimer’s disease
Mrdjen, D., Fox, E. J., Bukhari, S. A., Montine, K. S., Bendall, S. C., & Montine, T. J. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02054-4 · Cited by 162
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies
Zhao, N., Di, B., & Xu, L. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.06.002 · Cited by 161
The role of NOD-like receptors in innate immunity
Almeida-da-Silva, C. L. C., Savio, L. E. B., Coutinho‐Silva, R., & Ojcius, D. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122586 · Cited by 170
NLRP3 inflammasome activation in inflammaging
Latz, E., & Duewell, P. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.001 · Cited by 174
Self-citationNLRP3 inflammasome activation is associated with proliferative diabetic retinopathy
Loukovaara, S., Piippo, N., Kinnunen, K., Hytti, M., Kaarniranta, K., & Kauppinen, A. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13427 · Cited by 160
Grimaldi, A., Pediconi, N., Oieni, F., Pizzarelli, R., Rosito, M., Giubettini, M., Santini, T., Limatola, C., Ruocco, G., Ragozzino, D., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00925 · Cited by 153
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 162
Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease
Pennisi, M., Crupi, R., Di Paola, R., Ontario, M. L., Bella, R., Calabrese, E. J., Crea, R., Cuzzocrea, S., & Calabrese, V. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23986 · Cited by 157
Calabrese, V., Giordano, J., Signorile, A., Ontario, M. L., Castorina, S., Pasquale, C. D., Eckert, G. P., & Calabrese, E. J. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23925 · Cited by 157
Inflammasome activation and innate immunity in A lzheimer's disease
Heneka, M. T. (2016) · Brain Pathology · doi:10.1111/bpa.12483 · Cited by 157
Self-citationMohanty, A., Tiwari-Pandey, R., & Pandey, N. R. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00507-9 · Cited by 164
Inflammasomes: Threat-Assessment Organelles of the Innate Immune System
Evavold, C. L., & Kagan, J. C. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.005 · Cited by 159
Wei, P., Yang, F., Zheng, Q., Tang, W., & Li, J. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00073 · Cited by 155
Poh, L., Fann, D. Y., Wong, P., Lim, H. M., Foo, S. L., Kang, S.-W., Rajeev, V., Selvaraji, S., Iyer, V. R., Parathy, N., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00971-5 · Cited by 157
Jie, F., Yang, X., Yang, B., Liu, Y., Wu, L., & Lu, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113317 · Cited by 161
Land, W. G. (2015) · Sultan Qaboos University medical journal · doi:10.18295/2075-0528.1676 · Cited by 157
Arginase 1+ microglia reduce Aβ plaque deposition during IL-1β-dependent neuroinflammation
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0411-8 · Cited by 152
Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis ( EAE )
Barclay, W., & Shinohara, M. L. (2016) · Brain Pathology · doi:10.1111/bpa.12477 · Cited by 154
Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
Schwaid, A. G., & Spencer, K. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01307 · Cited by 154
Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1
Garber, C., Vasek, M. J., Vollmer, L. L., Sun, T., Jiang, X., & Klein, R. S. (2017) · Nature Immunology · doi:10.1038/s41590-017-0021-y · Cited by 152
Liu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., Schötz, K., Menger, M. D., Fassbender, K., & Liu, Y. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.01.011 · Cited by 149
Li, X., Thome, S., Ma, X., Amrute‐Nayak, M., Finigan, A. J., Kitt, L., Masters, L. M., James, J. R., Shi, Y., Meng, G., et al. (2017) · Nature Communications · doi:10.1038/ncomms15986 · Cited by 160
Klotho controls the brain-immune system interface in the choroid plexus
Zhu, L., Stein, L. R., Kim, D., Ho, K., Yu, G.-Q., Zhan, L., Larsson, T. E., & Mucke, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808609115 · Cited by 148
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 149
Activation of the NLRP 3 inflammasome in microglia: the role of ceramide
Scheiblich, H., Schlütter, A., Golenbock, D. T., Latz, E., Martinez‐Martinez, P., & Heneka, M. T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14225 · Cited by 147
Self-citationCXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s disease model
Krauthausen, M., Kummer, M. P., Zimmermann, J., Reyes-Irisarri, E., Terwel, D., Bulic, B., Heneka, M. T., & Müller, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66771 · Cited by 152
Self-citationAMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging
Cordero, M. D., Williams, M. R., & Ryffel, B. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.10.009 · Cited by 149
The physiology of foamy phagocytes in multiple sclerosis
Grajchen, E., Hendriks, J. J. A., & Bogie, J. F. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0628-8 · Cited by 160
Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation
Ohto, U., Kamitsukasa, Y., Ishida, H., Zhang, Z., Murakami, K., Hirama, C., Maekawa, S., & Shimizu, T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121353119 · Cited by 152
Mulay, S. R., & Anders, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601611 · Cited by 154
Zhang, X., Xu, A., Lv, J., Zhang, Q., Ran, Y., Wei, C., & Wu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111822 · Cited by 148
Roles and Mechanisms of Gut Microbiota in Patients With Alzheimer’s Disease
Wu, S., Liu, X., Jiang, R., Yan, X., & Ling, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.650047 · Cited by 150
Glial cells in Alzheimer’s disease: From neuropathological changes to therapeutic implications
Uddin, M. S., & Lim, L. W. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101622 · Cited by 154
Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions
Hou, Y., Chu, X., Park, J., Zhu, Q., Hussain, M., Li, Z., Madsen, H. B., Yang, B., Wei, Y., Wang, Y., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13847 · Cited by 145
Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer’s disease
Taylor, J. M., Minter, M. R., Newman, A. G., Zhang, M., Adlard, P. A., & Crack, P. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.089 · Cited by 145
Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
Xu, G., Fu, S., Zhan, X., Wang, Z., Zhang, P., Shi, W., Qin, N., Chen, Y., Wang, C., Niu, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134601 · Cited by 143
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer’s disease
Thapa, P., Upadhyay, S. P., Suo, W. Z., Singh, V., Gurung, P., Lee, E. S., Sharma, R., & Sharma, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104681 · Cited by 151
Kamma, E., Lasisi, W. O., Libner, C. D., Ng, H. S., & Plemel, J. R. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02408-y · Cited by 157
Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 154
The Role of the Inflammasome in Neurodegenerative Diseases
Piancone, F., La Rosa, F., Marventano, I., Saresella, M., & Clerici, M. (2021) · Molecules · doi:10.3390/molecules26040953 · Cited by 144
Vitamin B6 Prevents IL-1β Protein Production by Inhibiting NLRP3 Inflammasome Activation
Zhang, P., Tsuchiya, K., Kinoshita, T., Kushiyama, H., Suidasari, S., Hatakeyama, M., Imura, H., Katô, N., & Suda, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.743815 · Cited by 146
Neuroinflammatory responses in Alzheimer’s disease
Dansokho, C., & Heneka, M. T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1831-7 · Cited by 146
Self-citationStress-induced NLRP3 inflammasome activation negatively regulates fear memory in mice
Dong, Y., Li, S., Lu, Y., Li, X., Liao, Y., Peng, Z., Li, Y., Hou, L., Yuan, Z., & Cheng, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01842-0 · Cited by 148
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease
Anderton, H., Wicks, I. P., & Silke, J. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0455-8 · Cited by 152
Gontier, G., George, C., Chaker, Z., Holzenberger, M., & Aïd, S. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0343-15.2015 · Cited by 145
Singhrao, S. K., & Olsen, I. (2019) · Journal of Oral Microbiology · doi:10.1080/20002297.2018.1563405 · Cited by 145
Calderón‐Garcidueñas, L., Kulesza, R. J., Doty, R. L., D’Angiulli, A., & Torres‐Jardón, R. (2014) · Environmental Research · doi:10.1016/j.envres.2014.12.012 · Cited by 145
Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases
Tsubaki, H., Tooyama, I., & Walker, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249357 · Cited by 151
Brain Insulin Resistance in Alzheimer's Disease and its Potential Treatment with GLP-1 Analogs
Talbot, K. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.73 · Cited by 141
What is microglia neurotoxicity (Not)?
Biber, K. P. H., Owens, T., & Boddeke, E. (2014) · Glia · doi:10.1002/glia.22654 · Cited by 146
Inhibiting the Inflammasome: A Chemical Perspective
Baldwin, A. G., Brough, D., & Freeman, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01091 · Cited by 142
Arbore, G., & Kemper, C. (2016) · European Journal of Immunology · doi:10.1002/eji.201546131 · Cited by 145
Hafner‐Bratkovič, I., Sušjan, P., Lainšček, D., Tapia‐Abellán, A., Cerović, K., Kadunc, L., Angosto-Bazarra, D., Pelegrı́n, P., & Jerala, R. (2018) · Nature Communications · doi:10.1038/s41467-018-07573-4 · Cited by 145
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
He, X., Yang, W., Zeng, Z., Wei, Y., Gao, J., Zhang, B., Li, L., Liu, L., Wan, Y., Zeng, Q., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0260-y · Cited by 140
Talbot, K., & Wang, H.-Y. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.007 · Cited by 142
Mechanisms of NLRP3 priming in inflammaging and age related diseases
Gritsenko, A., Green, J., Brough, D., & López‐Castejón, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.08.003 · Cited by 146
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
Chen, Y., He, H., Lin, B., Chen, Y., Deng, X., Jiang, W., & Zhou, R. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00683-y · Cited by 142
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
Berlanga‐Acosta, J., Guillén, G. E., Rodríguez-Rodríguez, N., Bringas-Vega, M. L., García-del-Barco-Herrera, D., Berlanga-Saez, J. O., Ojalvo, A. G., Valdés-Sosa, M. J., & Valdes-Sosa, P. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560375 · Cited by 143
NLRP3 inflammasome in neurodegenerative disease
Anderson, F. L., Biggs, K. E., Rankin, B. E., & Havrda, M. C. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.006 · Cited by 154
Gong, T., Chen, Q., Mao, H., Zhang, Y., Ren, H., Xu, M., Chen, H., & Yang, D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925435 · Cited by 138
Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration
Ising, C., & Heneka, M. T. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0153-x · Cited by 140
Self-citationFulp, J., Liu, H., Toldo, S. A., Jiang, Y., Boice, A., Guo, C., Li, X., Rolfe, A., Sun, D., Abbate, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00733 · Cited by 138
Microglia in Alzheimer's Disease: Risk Factors and Inflammation
Katsumoto, A., Takeuchi, H., Takahashi, K., & Tanaka, F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00978 · Cited by 140
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease
Ghosh, A., Comerota, M. M., Wan, D., Chen, F., Propson, N. E., Hwang, S. H., Hammock, B. D., & Zheng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1206 · Cited by 139
Fu, W., Wang, X., & Ip, N. Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00402 · Cited by 138
Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer’s Disease
Kempuraj, D., Mentor, S., Thangavel, R., Ahmed, M. E., Selvakumar, G. P., Raikwar, S. P., Dubova, I., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00054 · Cited by 136
Inflammatory aspects of Alzheimer’s disease
Lucena, P. B., & Heneka, M. T. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02790-2 · Cited by 152
Self-citationMitochondria as a centrally positioned hub in the innate immune response
Sandhir, R., Halder, A., & Sunkaria, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.10.020 · Cited by 135
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry
Fanet, H., Capuron, L., Castanon, N., Calon, F., & Vancassel, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200729103529 · Cited by 134
Microglia in Alzheimer’s disease: A multifaceted relationship
ElAli, A., & Rivest, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.021 · Cited by 134
Inflammasomes and Metabolic Disease
Henao‐Mejia, J., Elinav, E., Thaiss, C. A., & Flavell, R. A. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170324 · Cited by 176
Mitochondria at the interface between neurodegeneration and neuroinflammation
Bader, V., & Winklhofer, K. F. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.028 · Cited by 135
The potential role of necroptosis in inflammaging and aging
Royce, G. H., Brown‐Borg, H. M., & Deepa, S. S. (2019) · GeroScience · doi:10.1007/s11357-019-00131-w · Cited by 137
The Role of Neuroinflammation in Dementias
Pasqualetti, G., Brooks, D. J., & Edison, P. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0531-7 · Cited by 133
The Role of Immunosenescence in Neurodegenerative Diseases
Costantini, E., D’Angelo, C., & Reale, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/6039171 · Cited by 133
Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome
Bai, H., Yang, B., Yu, W., Xiao, Y. C., Yu, D., & Zhang, Q. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.015 · Cited by 138
Wang, B., Shi, J., Ge, N.-N., Ou, Z., Tian, Y., Jiang, T., Zhou, J., Xu, J. L., & Zhang, Y.-D. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1178-5 · Cited by 133
Zhao, Y., Zeng, C., Li, X., Yang, T., Kuang, X., & Du, J. (2020) · Aging Cell · doi:10.1111/acel.13239 · Cited by 135
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease
Aso, E., & Ferrer, I. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00243 · Cited by 131
Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists
Morris, G., Walker, A. J., Berk, M., Maes, M. H. J., & Puri, B. K. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0793-y · Cited by 134
Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets
Vieira, M. N. N., Lima‐Filho, R. A. S., & Felice, F. G. D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.014 · Cited by 133
Soluble α-synuclein–antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia
Trudler, D., Nazor, K. L., Eisele, Y. S., Grabauskas, T., Dolatabadi, N., Parker, J., Sultan, A., Zhong, Z., Goodwin, M. S., Levites, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025847118 · Cited by 137
Zhang, X., Wang, Z., Zheng, Y., Yu, Q., Zeng, M., Bai, L., Yang, L., Guo, M., Jiang, X., & Gan, J. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5238 · Cited by 144
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
Inflammasomes: Molecular Regulation and Implications for Metabolic and Cognitive Diseases
Choi, A. J. S., & Ryter, S. W. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0104 · Cited by 132
Inflammasomes as therapeutic targets for A lzheimer's disease
White, C., Lawrence, C. B., Brough, D., & Rivers‐Auty, J. (2016) · Brain Pathology · doi:10.1111/bpa.12478 · Cited by 136
Metadata
- Authors
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock, D. T.
- Affiliations
- University of Bonn (DE)
- Technische Universität Braunschweig (DE)
- University of Massachusetts Chan Medical School (US)
- Center of Advanced European Studies and Research (DE)
- Corresponding author
- Heneka, Michael T.
- Latz, Eicke
- Golenbock, Douglas T.
- ORCID
- Venue
- Nature
- Published
- 2012-12-19
- Volume
- 493
- Issue
- 7434
- Pages
- 674-678
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3812809
- OpenAlex
- W1993976394
- Semantic Scholar
- 3a962c33176c94bc0dd8bfea4ebe2eb83be8a01e
- Cited by
- 2,898
- References
- 34
- Citations by year
- 2026: 274 · 2025: 270 · 2024: 273 · 2023: 270 · 2022: 306 · 2021: 314 · 2020: 261 · 2019: 203 · 2018: 187 · 2017: 147 · 2016: 117 · 2015: 112 · 2014: 99 · 2013: 62
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of General Medical Sciences (R01GM054060)
- National Institute of Allergy and Infectious Diseases (U19AI084048, R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, caspase-1, Alzheimer's disease, amyloid-beta, APP/PS1 mice, microglia, neuroinflammation, IL-1β, amyloid-beta clearance, spatial memory, NLRP3 knockout mice, cognitive impairment, therapeutic target
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Behavior, Animal, Brain, Carrier Proteins, Humans, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Gene Expression Regulation, Enzymologic, Amyloid beta-Peptides, Caspase 1, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta, Inflammasomes, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
